[Skip to Content]
[Skip to Content Landing]
Article
May 1960

Studies on the Biological Disposition of Griseofulvin, an Oral Antifungal Agent

Author Affiliations

Greenford, England

Glaxo Laboratories Limited, Greenford, Middlesex, England.

AMA Arch Derm. 1960;81(5):735-745. doi:10.1001/archderm.1960.03730050091016
Abstract

In 1958 Gentles3 reported that he had successfully eradicated experimental ringworm of guinea pigs by oral treatment with griseofulvin. Investigations into the value of this antibiotic against dermatophyte infections in man were immediately carried out (Blank and Roth,2 1958; Riehl,5 1958; Williams et al.,8 1959); the results have been reviewed with considerable enthusiasm (Sulzberger and Baer,7 1959). Despite our rapidly expanding knowledge of griseofulvin's clinical usefulness, little information is available on its distribution and fate in the body. Gentles et al.4 (1959) have demonstrated its presence in the hair of guinea pigs after they had been dosed orally with it. Sharpe and Tomich6 (1959), investigating the systemic toxicity of griseofulvin in mice and rats, found that the intraperitoneal toxicity was many times the oral. This finding suggests that, in high doses at least, griseofulvin is either poorly or slowly absorbed from the gastrointestinal

×